Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Akamai v. Limelight (1)
- Biologic drugs (1)
- Biologics Price Competition and Innovation Act (1)
- Biology (1)
- Decision making (1)
-
- Drugs (1)
- Equivalence (1)
- Federal agencies (1)
- Food and Drug Administration (1)
- Judicial interpretation (1)
- Judicial review (1)
- Law reform (1)
- Legislative interpretation (1)
- Liability (1)
- Molecular structure (1)
- Obviousness (1)
- Patent infringement (1)
- Patentability (1)
- Pharmaceuticals (1)
- Similarity (1)
- Technology (1)
Articles 1 - 2 of 2
Full-Text Articles in Law
Interactive Methods And Collaborative Performance: A New Future For Indirect Infringement, Josh Rychlinski
Interactive Methods And Collaborative Performance: A New Future For Indirect Infringement, Josh Rychlinski
Michigan Telecommunications & Technology Law Review
An individual is liable for patent infringement if he infringes one or more patented claims either directly under 35 U.S.C. § 271(a) or indirectly under 35 U.S.C. § 271(b) or § 271(c). In 2012, the Federal Circuit clarified its interpretation of § 271(b) and § 271(c) in the case of Akamai v. Limelight. However, the court failed to address issues of “divided” direct infringement, where two or more entities combine and together complete each and every step of a method claim, but no single entity does all of the steps. This Note walks through the history of the judicial interpretation …
Interpreting Biological Similarity: Ongoing Challenges For Diverse Decision Makers, Sarah M. Cork
Interpreting Biological Similarity: Ongoing Challenges For Diverse Decision Makers, Sarah M. Cork
Michigan Telecommunications & Technology Law Review
Similarity is an elusive and complicated concept facing comparisons of biological molecules, as even minute changes to a molecule's structure can dramatically affect its function in the body. Yet the flood of biologic drugs on the market will increasingly force these similarity comparisons. These concerns are particularly relevant to two groups of drugs: families of biologic drugs that closely resemble each other in structure and function, here termed "similar-impact biologics," and the biosimilars, which are intended to closely approximate generic forms of biologic drugs. In bringing biologic drugs to the market, manufacturers are likely to face dual obstacles: FDA approval …